Titre
The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy.
Type
synthèse (review)
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Pasero, C.
Auteure/Auteur
Speiser, D.E.
Auteure/Auteur
Derré, L.
Auteure/Auteur
Olive, D.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
1471-4973
Statut éditorial
Publié
Date de publication
2012
Volume
12
Numéro
4
Première page
478
Dernière page/numéro d’article
485
Langue
anglais
Résumé
The regulation of the immune system is controlled by many cell surface receptors. A prominent representative is the 'molecular switch' HVEM (herpes virus entry mediator) that can activate either proinflammatory or inhibitory signaling pathways. HVEM ligands belong to two distinct families: the TNF-related cytokines LIGHT and lymphotoxin-α, and the Ig-related membrane proteins BTLA and CD160. HVEM and its ligands have been involved in the pathogenesis of various autoimmune and inflammatory diseases, but recent reports indicate that this network may also be involved in tumor progression and resistance to immune response. Here we summarize the recent advances made regarding the knowledge on HVEM and its ligands in cancer cells, and their potential roles in tumor progression and escape to immune responses. Blockade or enhancement of these pathways may help improving cancer therapy.
PID Serval
serval:BIB_673AC528840D
PMID
Open Access
Oui
Date de création
2012-11-22T13:26:32.353Z
Date de création dans IRIS
2025-05-20T21:51:46Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
BIB_673AC528840D.P001.pdf
Version du manuscrit
published
Taille
596.83 KB
Format
Adobe PDF
PID Serval
serval:BIB_673AC528840D.P001
URN
urn:nbn:ch:serval-BIB_673AC528840D1
Somme de contrôle
(MD5):2476a95958b0fd0cd8e96e72f13dde7d